Internal Medicine, Gastroenterology · Rutland, VT
NPI
1679554539
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1 Albert Cree Dr
Rutland, VT, 05701
Phone (802) 786-1400
Groups this clinician bills Medicare through
Medicare paid, 2024
$722K
43,642 services
Medicare patients, 2024
170
Average age 72
Drug cost, 2024
$2.5M
746 prescriptions
Company payments, 2025
$95K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip Ginsburg was code J3380 (injection, vedolizumab, intravenous, 1 mg), 28,800 times for 20 patients. In total Philip Ginsburg billed 43,642 services in 44 codes, and Medicare paid $722K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 28,800 | 20 | $17.44 | $502K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 5,132 | 19 | $24.73 | $127K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 191 | 42 | $0.52 | $98.86 |
| 96413 Chemotherapy Administration | Office | 99 | 26 | $116.53 | $12K |
| 96415 Chemotherapy Administration | Office | 95 | 22 | $24.68 | $2,345 |
| 96365 Intravenous Infusion, Hydration | Office | 94 | 19 | $56.34 | $5,296 |
| 99214 Office E&M - Established | Office | 60 | 42 | $106.31 | $6,379 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 49 | 36 | $13.34 | $654 |
| 45385 Colonoscopy - Lesion Removal | Facility | 37 | 37 | $223.57 | $8,272 |
| 45380 Lower GI Endoscopy - Other | Facility | 30 | 29 | $94.75 | $2,843 |
| 99213 Office E&M - Established | Office | 22 | 20 | $71.70 | $1,577 |
| 43239 Upper GI Endoscopy | Facility | 19 | 19 | $80.30 | $1,526 |
| 99215 Office E&M - Established | Office | 12 | 11 | $148.54 | $1,782 |
| 99222 Hospital E&M - Initial | Facility | 12 | 11 | $107.29 | $1,287 |
By year: 2022 $546K for 49,675 services; 2023 $696K for 50,233 services; 2024 $722K for 43,642 services.
Medicare prescription drug claims, 2024
In 2024, the drug Philip Ginsburg prescribed most often to Medicare patients was Mesalamine, with 93 prescriptions and refills. In total Philip Ginsburg wrote 746 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mesalamine Generic | 93 | 259 | 23 | $83K |
| Stelara Ustekinumab | 63 | 75 | Under 11 | $1.8M |
| Omeprazole Generic | 50 | 134 | 17 | $629 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 37 | 37 | 33 | $488 |
| Pantoprazole Sodium Generic | 35 | 103 | 13 | $310 |
| Esomeprazole Magnesium Generic | 28 | 72 | 11 | $820 |
| Dicyclomine Hcl Generic | 25 | 63 | 11 | $548 |
| Cholestyramine Cholestyramine (With Sugar) | 24 | 55 | Under 11 | $1,951 |
| Desipramine Hcl Generic | 23 | 33 | Under 11 | $903 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 23 | 23 | 23 | $1,388 |
| Azathioprine Generic | 22 | 42 | Under 11 | $572 |
| Inflectra Infliximab-Dyyb | 21 | 26 | Under 11 | $145K |
| Methotrexate Methotrexate Sodium | 20 | 54 | Under 11 | $364 |
| Xeljanz Xr Tofacitinib Citrate | 17 | 25 | Under 11 | $141K |
| Colestipol Hcl Generic | 16 | 46 | Under 11 | $2,416 |
Brand drugs: - claims; generic drugs: 534 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Philip Ginsburg $95K ($95K in general payments such as food, travel and fees) from 10 companies. The largest payer was Janssen Biotech, Inc. with $71K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.